Akèy › Myelom Miltip › Minnesota
Etid klinik pou Myelom Miltip nan Minnesota
30 etid pou Myelom Miltip ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
- Mayo Clinic in Rochester, Rochester
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07850284A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Mayo Clinic, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07393282A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- University Of Minnesota Medical Center, Minneapolis
- Mayo Clinic, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06465316A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Minnesota Oncology - Minneapolis Clinic /ID# 278720, Minneapolis
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07095452Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Minnesota, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06375044Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06940297Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Minnesota Oncology Hematology PA-Chaska, Chaska
- ak 24 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Mayo Clinic - Transplant Center - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Minneapolis
- Research Site, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Mayo Clinic Health System-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06630104A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Minnesota, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Minnesota, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic - Rochester /ID# 251164, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Mayo Clinic, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Riverwood Healthcare Center, Aitkin
- Essentia Health-St. Joseph's Medical Center, Brainerd
- Essentia Health - Duluth Clinic, Duluth
- ak 2 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2026 · NCT06785415Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Jun 25, 2026 · NCT03314974Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- ak 40 plis
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT03017820Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- University of Minnesota - Masonic Cancer Center, Minneapolis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 5, 2026 · NCT03858205Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Minnesota Oncology Hematology, Minneapolis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT05972135Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
Ap rekrite
Laj 65 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT06145581cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Oct 14, 2025 · NCT00626496IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University of Minnesota, Minneapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2025 · NCT06119685Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- Center for International Blood and Marrow Transplant Research, Minneapolis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Aug 30, 2023 · NCT03127761Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.